Rein 3D PRINT MECHANICS
Launched by UNIVERSITY HOSPITAL, BORDEAUX · Jul 25, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The Rein 3D PRINT MECHANICS trial is a research study focused on understanding how different imaging techniques can help analyze the elasticity of both healthy and cancerous kidney tissues. This study aims to improve the accuracy of 3D models that urologists use during surgery, which could lead to better treatment plans for kidney cancer. The main goal is to create a model that predicts how normal and abnormal kidney tissues behave based on advanced imaging called Magnetic Resonance elastography (a special type of MRI).
To participate in this study, individuals must be adults aged 18 and older who are scheduled for kidney surgery at Bordeaux University Hospital and have had a CT scan. They also need to agree to share their information with a specific database for research purposes. However, certain people may not be eligible, including those who are pregnant, have specific medical conditions that prevent MRI scans, or have certain types of tumors. If you join the trial, you can expect to undergo a variety of imaging tests alongside your regular medical treatment, which could help improve kidney cancer care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (≥ 18 years of age)
- • Scheduled for surgical management with nephrectomy for kidney tumor in the urology department of Bordeaux University Hospital
- • CT scan available or scheduled for surgery
- • Consent expressed for integration of the UroCCR database
- • Expressed consent for participation in the Rein 3D Print Mechanics study
- • Patients affiliated or benefiting from social security system
- Exclusion Criteria:
- • - Pregnant or breast-feeding women
- • Contraindication to MRI (Magnetic Resonance Imaging)
- • Contraindication to injection of gadoline contrast agents
- • Biopsy prior to MRI, CT and ultrasound scans (risk of artifactual alteration, via iatrogenic hemorrhagic changes, of the biomechanical properties of the renal tumor and parenchyma).
- • Presence of thoracolumbar arthrodesis material
- • Obese patient (body mass index ≥ 30 kg/m²)
- • Cystic renal tumors with solid component (corresponding to either parietal thickening or tumor bud) \< 2 cm
- • Necrotic renal tumors with solid component (corresponding to either parietal thickening or tumor bud) \< 2 cm
- • Ascites
- • Person under legal protection
- • Difficulty understanding and expressing in French
About University Hospital, Bordeaux
The University Hospital of Bordeaux is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution integrates cutting-edge scientific inquiry with patient care, fostering an environment that encourages collaboration among multidisciplinary teams. With a commitment to improving treatment outcomes and enhancing patient safety, the University Hospital of Bordeaux plays a pivotal role in the development of new therapies and medical technologies, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bordeaux, , France
Bordeaux, , France
Patients applied
Trial Officials
JAMBON EVA, Dr
Principal Investigator
University Hospital, Bordeaux
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported